Long-Term Follow-Up of Thalassemia Major Patients with Hepatitis C Virus Treated with Sofosbuvir and Daclatasvir: A Cohort Study

Fahimeh Safarnezhad Tameshkel; Mohammad Hadi Karbalaie Niya; Bahare Amirkalali; Nima Motamed; Jamshid Vafaeimanesh; Mansooreh Maadi; Masodreza Sohrabi; Amir Hossein Faraji; Mahmoodreza Khoonsari; Hossein Ajdarkosh; Mehdi Nikkhah; Elham Sobrakhshankhah; Farhad Zamani

doi:10.1016/j.arcmed.2022.09.004

Long-Term Follow-Up of Thalassemia Major Patients with Hepatitis C Virus Treated with Sofosbuvir and Daclatasvir: A Cohort Study

Fahimeh Safarnezhad Tameshkel, Mohammad Hadi Karbalaie Niya, Bahare Amirkalali, Nima Motamed, Jamshid Vafaeimanesh, Mansooreh Maadi, Masodreza Sohrabi, Amir Hossein Faraji, Mahmoodreza Khoonsari, Hossein Ajdarkosh, Mehdi Nikkhah, Elham Sobrakhshankhah, Farhad Zamani

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: Treatment of Chronic Hepatitis C virus (HCV) infection in patients suffering from hereditary β-thalassemia major is a concern due to drug complications and liver malfunction. The aim of the present study was to evaluate treatment outcome of Direct-Acting Antiviral (DAA) therapy in thalassemia major patients infected with HCV in a three year follow-up.

METHODS: In a cohort study, long-term safety and efficacy of DAA therapy were evaluated in a group of thalassemia major patients suffering from chronic HCV infection. Hematologic and biochemical parameters as well as liver Fibroscan monitoring were assessed at the onset and three years after the treatment.

RESULTS: From among 84 patients enrolled in the study, 53.6% were males, 36.9% had cirrhosis, 96.4% had a history of Desferal usage, and 78.6% had a history of splenectomy. Unfortunately, 7 participants (8.3%) died prior to the end of follow-up with nearly half of them having Iron overload and heart failure complications. Fibroscan score, ALT, AST, and ferritin were significantly lower compared with baseline evaluation, while Hb, creatinine, and direct bilirubin increased significantly in the third year after the treatment.

CONCLUSION: Safety and efficacy of Sofosbuvir and Daclatasvir in thalassemia patients assessed previously but our three year follow-up showed their mild complications and death into a long-term period after DAAs treatment and 91.7% three year survival rate, which may affected by other confounding factors, such as liver malfunction and Iron overload.

Original language	English (US)
Pages (from-to)	666-672
Number of pages	7
Journal	Archives of Medical Research
Volume	53
Issue number	7
DOIs	https://doi.org/10.1016/j.arcmed.2022.09.004
State	Published - Nov 2022

Keywords

Humans
Male
Female
Sofosbuvir/therapeutic use
Hepacivirus/genetics
Antiviral Agents/therapeutic use
Hepatitis C, Chronic/complications
Follow-Up Studies
Cohort Studies
beta-Thalassemia/complications
Hepatitis C/complications
Pyrrolidines/therapeutic use
Treatment Outcome
Iron Overload
Drug Therapy, Combination

Access to Document

10.1016/j.arcmed.2022.09.004

Cite this

Safarnezhad Tameshkel, F., Karbalaie Niya, M. H., Amirkalali, B., Motamed, N., Vafaeimanesh, J., Maadi, M., Sohrabi, M., Faraji, A. H., Khoonsari, M., Ajdarkosh, H., Nikkhah, M., Sobrakhshankhah, E., & Zamani, F. (2022). Long-Term Follow-Up of Thalassemia Major Patients with Hepatitis C Virus Treated with Sofosbuvir and Daclatasvir: A Cohort Study. Archives of Medical Research, 53(7), 666-672. https://doi.org/10.1016/j.arcmed.2022.09.004

Safarnezhad Tameshkel, F, Karbalaie Niya, MH, Amirkalali, B, Motamed, N, Vafaeimanesh, J, Maadi, M, Sohrabi, M, Faraji, AH, Khoonsari, M, Ajdarkosh, H, Nikkhah, M, Sobrakhshankhah, E & Zamani, F 2022, 'Long-Term Follow-Up of Thalassemia Major Patients with Hepatitis C Virus Treated with Sofosbuvir and Daclatasvir: A Cohort Study', Archives of Medical Research, vol. 53, no. 7, pp. 666-672. https://doi.org/10.1016/j.arcmed.2022.09.004

@article{7d58cd0df9e0459d91cd14e1b1d382d6,

title = "Long-Term Follow-Up of Thalassemia Major Patients with Hepatitis C Virus Treated with Sofosbuvir and Daclatasvir: A Cohort Study",

abstract = "BACKGROUND: Treatment of Chronic Hepatitis C virus (HCV) infection in patients suffering from hereditary β-thalassemia major is a concern due to drug complications and liver malfunction. The aim of the present study was to evaluate treatment outcome of Direct-Acting Antiviral (DAA) therapy in thalassemia major patients infected with HCV in a three year follow-up.METHODS: In a cohort study, long-term safety and efficacy of DAA therapy were evaluated in a group of thalassemia major patients suffering from chronic HCV infection. Hematologic and biochemical parameters as well as liver Fibroscan monitoring were assessed at the onset and three years after the treatment.RESULTS: From among 84 patients enrolled in the study, 53.6% were males, 36.9% had cirrhosis, 96.4% had a history of Desferal usage, and 78.6% had a history of splenectomy. Unfortunately, 7 participants (8.3%) died prior to the end of follow-up with nearly half of them having Iron overload and heart failure complications. Fibroscan score, ALT, AST, and ferritin were significantly lower compared with baseline evaluation, while Hb, creatinine, and direct bilirubin increased significantly in the third year after the treatment.CONCLUSION: Safety and efficacy of Sofosbuvir and Daclatasvir in thalassemia patients assessed previously but our three year follow-up showed their mild complications and death into a long-term period after DAAs treatment and 91.7% three year survival rate, which may affected by other confounding factors, such as liver malfunction and Iron overload.",

keywords = "Humans, Male, Female, Sofosbuvir/therapeutic use, Hepacivirus/genetics, Antiviral Agents/therapeutic use, Hepatitis C, Chronic/complications, Follow-Up Studies, Cohort Studies, beta-Thalassemia/complications, Hepatitis C/complications, Pyrrolidines/therapeutic use, Treatment Outcome, Iron Overload, Drug Therapy, Combination",

author = "{Safarnezhad Tameshkel}, Fahimeh and {Karbalaie Niya}, {Mohammad Hadi} and Bahare Amirkalali and Nima Motamed and Jamshid Vafaeimanesh and Mansooreh Maadi and Masodreza Sohrabi and Faraji, {Amir Hossein} and Mahmoodreza Khoonsari and Hossein Ajdarkosh and Mehdi Nikkhah and Elham Sobrakhshankhah and Farhad Zamani",

year = "2022",

month = nov,

doi = "10.1016/j.arcmed.2022.09.004",

language = "English (US)",

volume = "53",

pages = "666--672",

journal = "Archives of Medical Research",

issn = "0188-4409",

publisher = "Elsevier",

number = "7",

}

TY - JOUR

T1 - Long-Term Follow-Up of Thalassemia Major Patients with Hepatitis C Virus Treated with Sofosbuvir and Daclatasvir

T2 - A Cohort Study

AU - Safarnezhad Tameshkel, Fahimeh

AU - Karbalaie Niya, Mohammad Hadi

AU - Amirkalali, Bahare

AU - Motamed, Nima

AU - Vafaeimanesh, Jamshid

AU - Maadi, Mansooreh

AU - Sohrabi, Masodreza

AU - Faraji, Amir Hossein

AU - Khoonsari, Mahmoodreza

AU - Ajdarkosh, Hossein

AU - Nikkhah, Mehdi

AU - Sobrakhshankhah, Elham

AU - Zamani, Farhad

PY - 2022/11

Y1 - 2022/11

N2 - BACKGROUND: Treatment of Chronic Hepatitis C virus (HCV) infection in patients suffering from hereditary β-thalassemia major is a concern due to drug complications and liver malfunction. The aim of the present study was to evaluate treatment outcome of Direct-Acting Antiviral (DAA) therapy in thalassemia major patients infected with HCV in a three year follow-up.METHODS: In a cohort study, long-term safety and efficacy of DAA therapy were evaluated in a group of thalassemia major patients suffering from chronic HCV infection. Hematologic and biochemical parameters as well as liver Fibroscan monitoring were assessed at the onset and three years after the treatment.RESULTS: From among 84 patients enrolled in the study, 53.6% were males, 36.9% had cirrhosis, 96.4% had a history of Desferal usage, and 78.6% had a history of splenectomy. Unfortunately, 7 participants (8.3%) died prior to the end of follow-up with nearly half of them having Iron overload and heart failure complications. Fibroscan score, ALT, AST, and ferritin were significantly lower compared with baseline evaluation, while Hb, creatinine, and direct bilirubin increased significantly in the third year after the treatment.CONCLUSION: Safety and efficacy of Sofosbuvir and Daclatasvir in thalassemia patients assessed previously but our three year follow-up showed their mild complications and death into a long-term period after DAAs treatment and 91.7% three year survival rate, which may affected by other confounding factors, such as liver malfunction and Iron overload.

AB - BACKGROUND: Treatment of Chronic Hepatitis C virus (HCV) infection in patients suffering from hereditary β-thalassemia major is a concern due to drug complications and liver malfunction. The aim of the present study was to evaluate treatment outcome of Direct-Acting Antiviral (DAA) therapy in thalassemia major patients infected with HCV in a three year follow-up.METHODS: In a cohort study, long-term safety and efficacy of DAA therapy were evaluated in a group of thalassemia major patients suffering from chronic HCV infection. Hematologic and biochemical parameters as well as liver Fibroscan monitoring were assessed at the onset and three years after the treatment.RESULTS: From among 84 patients enrolled in the study, 53.6% were males, 36.9% had cirrhosis, 96.4% had a history of Desferal usage, and 78.6% had a history of splenectomy. Unfortunately, 7 participants (8.3%) died prior to the end of follow-up with nearly half of them having Iron overload and heart failure complications. Fibroscan score, ALT, AST, and ferritin were significantly lower compared with baseline evaluation, while Hb, creatinine, and direct bilirubin increased significantly in the third year after the treatment.CONCLUSION: Safety and efficacy of Sofosbuvir and Daclatasvir in thalassemia patients assessed previously but our three year follow-up showed their mild complications and death into a long-term period after DAAs treatment and 91.7% three year survival rate, which may affected by other confounding factors, such as liver malfunction and Iron overload.

KW - Humans

KW - Male

KW - Female

KW - Sofosbuvir/therapeutic use

KW - Hepacivirus/genetics

KW - Antiviral Agents/therapeutic use

KW - Hepatitis C, Chronic/complications

KW - Follow-Up Studies

KW - Cohort Studies

KW - beta-Thalassemia/complications

KW - Hepatitis C/complications

KW - Pyrrolidines/therapeutic use

KW - Treatment Outcome

KW - Iron Overload

KW - Drug Therapy, Combination

U2 - 10.1016/j.arcmed.2022.09.004

DO - 10.1016/j.arcmed.2022.09.004

M3 - Article

C2 - 36216685

SN - 0188-4409

VL - 53

SP - 666

EP - 672

JO - Archives of Medical Research

JF - Archives of Medical Research

IS - 7

ER -

Long-Term Follow-Up of Thalassemia Major Patients with Hepatitis C Virus Treated with Sofosbuvir and Daclatasvir: A Cohort Study

Abstract

Keywords

Access to Document

Fingerprint

Cite this